
Hermetica Superfood Encyclopedia
Legacy index-continuity record: the score and narrative are provisional and must not be represented as validated or human-approved.
Review flags: AWAITING_SEMANTIC_VALIDATION
Brown seaweed powder contains fucoidan, which inhibits dipeptidyl peptidase-IV with an IC₅₀ of 1.11 μg/mL and suppresses MAPK p38 signaling pathways more effectively than specific inhibitors. The powder's phlorotannins modulate NF-κB, PI3k/Akt, and MAPK pathways while activating the Nrf2 pathway to increase cytoprotective enzyme expression.

Reported Benefits (Provisional)
Origin & History

Brown Seaweed Powder is derived from various species of brown algae, such as Ascophyllum nodosum and Fucus vesiculosus, native to the cold, nutrient-rich waters of the North Atlantic Ocean. It is primarily harvested from coastal regions of Canada, Ireland, and Norway. This marine superfood is valued for its exceptional mineral density and unique bioactive compounds, making it a cornerstone for metabolic and immune support.
Research Narrative (Provisional)
Numerous studies, including in vitro and animal models, support brown seaweed's role in thyroid health due to its iodine content, the detoxification benefits of fucoidan, and its broad antioxidant properties. Research also highlights its potential for metabolic support and anti-inflammatory effects, with ongoing human trials exploring these applications.
Preparation & Dosage
Dosage guidance is withheld because the publication gate has not recorded adequate support for this profile.
Nutritional Profile
- Dietary Fiber: Alginates, supporting digestion and detoxification. - Iodine: Essential for thyroid hormone production. - Minerals: Potassium, magnesium, calcium, zinc, selenium. - Vitamins: Vitamin C. - Fucoidan: Sulfated polysaccharide with detoxifying and immune-modulating properties. - Polyphenols & Carotenoids: Potent antioxidants, including fucoxanthin.
Reported Mechanism (Provisional)
Fucoidan inhibits dipeptidyl peptidase-IV (IC₅₀ 1.11 μg/mL) and hyaluronidase enzyme (IC₅₀ 2.9 μg/mL) while suppressing MAPK p38 signaling. Phlorotannins modulate NF-κB, PI3k/Akt, and MAPK pathways, block epidermal growth factor receptor binding, and suppress ERK1/ERK2 and JNK activation. Fucoxanthin and other carotenoids activate the Nrf2 pathway, increasing expression of phase II detoxification enzymes and antioxidant proteins.
Clinical Narrative (Provisional)
Current evidence is primarily based on in vitro studies and animal models rather than large-scale human clinical trials. Laboratory studies demonstrate antihypertensive activity (≤59.77%) and α-glucosidase inhibitory activity (≤68.05%), with fucoidan showing concentration-dependent anti-inflammatory effects superior to standard inhibitors. Brown seaweed extracts substantially decreased cancer cell development in breast cancer cell lines (MDA-MB-231 and MCF7). Human clinical trials are ongoing but limited published data is available for comprehensive clinical assessment.
Also Known As
Research updates — and 25% off your first order
Join our list for source-aware wellness education, review-state updates, and product news — and unlock 25% off your first Hermetica order. Educational content is not medical advice. No spam, unsubscribe anytime.







